Company Profile
Bacteromic Sp. z o.o. is a pioneering MedTech start-up founded in 2017 to develop and commercialise BACTEROMIC, a diagnostic system designed to address one of the most important challenges in modern medicine – multidrug resistance of bacterial pathogens.
Approach to Healthcare
Bacteromic Sp. z o.o. is developing the most comprehensive BACTEROMIC system for automatic antibiotic susceptibility testing (AST). Our intention is to provide reliable results for defining efficient treatment for bacterial infections in the shortest possible time to save the lives and health of patients and reduce the development of antibiotic resistance.
Impact of Products/Services on Healthcare:
The BACTEROMIC system allows for a one-time identification of the effectiveness of range of antibiotics used in the treatment of, among others, respiratory, blood, urinary tract, and skin infections. It provides a quick and accurate assessment of the antibiotic susceptibility of both Gram+ and Gram- bacteria in a single diagnostic panel.
Innovation
BACTEROMIC is revolutionising antibiotic susceptibility testing by elevating it to the next level by offering a comprehensive system that identifies the most effective antibiotic among all commonly used options for treating a specific bacterial infection. All this is available in a single panel with up to 60 assays (susceptibility to antibiotics or resistance mechanism detection) and up to 600 dilutions total, providing a precise minimal inhibitory concentration (MIC) estimation.
Future Direction
Increased automation using BACTEROMIC system, speed, improved usability and reliability of results enables higher patient/work throughput with less resources. The lifecycle of existing and newly developed antibiotics can be prolonged. Smarter treatment design supported with information reach susceptibility test results can defer resistance gain importantly and make any drug (currently used in clinical practice or invented in the future) be effective over a longer period of time. The deployment of affordable, widely available, automated AI-based diagnostic tests will expedite the detection and monitoring of resistant strains. This could play a vital role in controlling resistance spread in the ecosystem, a factor essential for public health.